Literature DB >> 18575765

Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism.

Teresa Gómez Del Pulgar1, Fátima Valdés-Mora, Eva Bandrés, Rosa Pérez-Palacios, Carolina Espina, Paloma Cejas, Miguel Angel García-Cabezas, Manuel Nistal, Enrique Casado, Manuel González-Barón, Jesús García-Foncillas, Juan Carlos Lacal.   

Abstract

Cdc42, a member of Rho GTPases family, is involved in the regulation of several cellular functions, such as rearrangement of actin cytoskeleton, membrane trafficking, cell-cycle progression, and transcriptional regulation. Aberrant expression or activity of Cdc42 has been reported in several tumours. Here, the specific role of Cdc42 in development and progression of colorectal cancer was analyzed through microarrays technology. A comparative analysis of Cdc42 overexpressing cells versus cells with decreased Cdc42 levels through siRNA revealed that Cdc42 overexpression down-regulated the potential tumour suppressor gene ID4. Results were validated by quantitative RT-PCR and the methylation status of the specific promoter, analyzed. Methylation-specific PCR and bisulfite sequencing PCR analysis revealed that Cdc42 induced the methylation of the CpG island of the ID4 promoter. Colorectal adenocarcinoma samples were compared with the corresponding adjacent normal tissue of the same patient in order to determine specific gene expression levels. The downregulation of ID4 by Cdc42 was also found of relevance in colorectal adenocarcinoma biopsies. Cdc42 was found to be overexpressed with high incidence (60%) in colorectal cancer samples, and this expression was associated with silencing of ID4 with statistical significance (p<0.05). Cdc42 may have a role in the development of colon cancer. Furthermore, inhibition of Cdc42 activity may have a direct impact in the management of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575765

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  49 in total

1.  A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR.

Authors:  Rainer Claus; Stefan Wilop; Thomas Hielscher; Miriam Sonnet; Edgar Dahl; Oliver Galm; Edgar Jost; Christoph Plass
Journal:  Epigenetics       Date:  2012-07-01       Impact factor: 4.528

2.  Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.

Authors:  Shih-Shih Chen; Rainer Claus; David M Lucas; Lianbo Yu; Jiang Qian; Amy S Ruppert; Derek A West; Katie E Williams; Amy J Johnson; Fred Sablitzky; Christoph Plass; John C Byrd
Journal:  Blood       Date:  2010-11-22       Impact factor: 22.113

Review 3.  Cdc42 in oncogenic transformation, invasion, and tumorigenesis.

Authors:  Kristy Stengel; Yi Zheng
Journal:  Cell Signal       Date:  2011-04-16       Impact factor: 4.315

4.  High Expression of Cell Division Cycle 42 Promotes Pancreatic Cancer Growth and Predicts Poor Outcome of Pancreatic Cancer Patients.

Authors:  Dejun Yang; Yu Zhang; Yajun Cheng; Liang Hong; Changming Wang; Ziran Wei; Qingping Cai; Ronglin Yan
Journal:  Dig Dis Sci       Date:  2017-02-08       Impact factor: 3.199

5.  Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by quantitative phosphoproteomics.

Authors:  Florian Gnad; Amy Young; Wei Zhou; Karen Lyle; Christy C Ong; Matthew P Stokes; Jeffrey C Silva; Marcia Belvin; Lori S Friedman; Hartmut Koeppen; Audrey Minden; Klaus P Hoeflich
Journal:  Mol Cell Proteomics       Date:  2013-04-22       Impact factor: 5.911

6.  Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.

Authors:  Hyun Chang; Sun Young Rha; Hei-Cheul Jeung; Jae-Jun Jung; Tae Soo Kim; Ho Jeong Kwon; Byung Soo Kim; Hyun Cheol Chung
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-09       Impact factor: 4.553

Review 7.  Pleiotropic functions of Rho GTPase signaling: a Trojan horse or Achilles' heel for breast cancer treatment?

Authors:  P R McHenry; T Vargo-Gogola
Journal:  Curr Drug Targets       Date:  2010-09       Impact factor: 3.465

8.  CDC42 inhibition suppresses progression of incipient intestinal tumors.

Authors:  Ryotaro Sakamori; Shiyan Yu; Xiao Zhang; Andrew Hoffman; Jiaxin Sun; Soumyashree Das; Pavan Vedula; Guangxun Li; Jiang Fu; Francesca Walker; Chung S Yang; Zheng Yi; Wei Hsu; Da-Hai Yu; Lanlan Shen; Alexis J Rodriguez; Makoto M Taketo; Edward M Bonder; Michael P Verzi; Nan Gao
Journal:  Cancer Res       Date:  2014-08-11       Impact factor: 12.701

9.  Network cluster analysis of protein-protein interaction network identified biomarker for early onset colorectal cancer.

Authors:  Tiancheng Luo; Shengdi Wu; Xizhong Shen; Lei Li
Journal:  Mol Biol Rep       Date:  2013-11-07       Impact factor: 2.316

10.  Human synthetic lethal inference as potential anti-cancer target gene detection.

Authors:  Nuria Conde-Pueyo; Andreea Munteanu; Ricard V Solé; Carlos Rodríguez-Caso
Journal:  BMC Syst Biol       Date:  2009-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.